The latest selling price of eflornithine (IWILFIN) tablets and price comparison across different channels

Eflornithine tablets (IWILFIN) is a new oral drug mainly used for the maintenance treatment of patients with high-risk neuroblastoma (HRNB). By inhibiting ornithine decarboxylase (ODC) activity, the drug can reduce the risk of tumor recurrence and improve patient long-term survival. As the first oral drug approved for this indication, IWILFIN has unique therapeutic value in clinical application.

Currently, eflornithine tablets have not yet been launched in mainland China, so the domestic price and medical insurance reimbursement information are not yet known. Domestic patients cannot obtain the drug directly through formal channels, nor can they pay for treatment through medical insurance reimbursement. This means that patients who want to use IWILFIN need to pay attention to overseas drug markets and related legal channels.

In overseas markets, IWILFINthe specification of the original drug is 192mg*100 tablets. Each box sells for about more than 10,000 US dollars, which is equivalent to about 700,000 yuan in RMB. The price may change due to exchange rate fluctuations. At present, there are no generic drugs on the market, so overseas purchase options mainly focus on original drugs, which imposes a greater financial burden on patients, and issues such as transportation and drug storage also need to be considered.

For domestic patients, the use of IWILFIN needs to be done under the guidance of a professional doctor to evaluate the indications and individualized treatment plan. While waiting for domestic launch and medical insurance inclusion, patients can pay attention to overseas drug information and clinical trial opportunities, but they should carefully choose legal and safe drug purchase channels to ensure reliable sources of drugs, and rationally evaluate efficacy and risks to obtain the best therapeutic effect.

Reference link:https://www.drugs.com